The Trump administration has withdrawn Heidi Overton’s nomination to lead the Food and Drug Administration, ending a confirmation effort that had faced uncertainty in the Senate. A White House official and a person close to Overton confirmed the decision, which removes the preventive care physician from consideration for one of the most consequential posts in US health policy.
The move came as the Senate’s health panel was preparing to act on the nomination. Concerns had emerged over whether Overton could count on enough Republican votes in committee, a necessary step before the nomination could advance to the full Senate. The committee vote had been expected on Wednesday, placing the White House decision at a sensitive moment in the confirmation process.
Late Tuesday, however, Sen. Bill Cassidy, the Louisiana Republican who leads the panel, publicly indicated that Overton had the support needed to clear the committee and proceed toward confirmation. In a post on X, Cassidy wrote: “Tonight, the White House abandoned a viable confirmation path for Dr. Overton.” His statement underscored the unusual timing of the withdrawal, coming after the committee chair said the votes were in place.
Overton, a preventive care doctor who previously served in the Trump White House, had been selected to oversee an agency with broad authority over medicines, vaccines, medical devices, tobacco products and much of the nation’s food supply. The FDA commissioner role is closely watched by the health industry, patient groups and lawmakers because the agency’s decisions affect drug approvals, safety monitoring and public health regulation.
The withdrawal leaves the administration without its chosen nominee for the agency’s top job and reopens the question of who will be put forward next. Any new nominee would need to face the same Senate review process, including scrutiny from the health committee and a final vote by the chamber. For the FDA, the leadership uncertainty comes at a time when its regulatory agenda remains central to debates over access to treatments, oversight standards and federal health governance.
